GP方案联合参麦注射液治疗晚期NSCLC临床观察  

Combination of Shenmei injection and GP chemotherapy for treatmen of advanced non-small cell lung cancer

作　　者：仲几春 张道松 朱云 

机构地区：[1]江苏省沭阳仁慈医院肿瘤内科

出　　处：《临床医药实践》2009年第8Z期1918-1920,共3页Proceeding of Clinical Medicine

摘　　要：目的:探讨参麦注射液在GP方案化疗晚期非小细胞肺癌(NSCLC)治疗中的作用。方法:选择经病理证实为非小细胞肺癌61例,以参麦注射液联合化疗作为实验组(31例),与30例单纯化疗组对照,观察其疗效、毒副作用、KPS评分改变、细胞免疫功能等。结果:实验组CR十PR为45.2%,略高于对照组的40%,但PR+CR+MD达74.2%,显著高于照组。可部分减低毒副作用,显著改善KPS。且CD4/CD8比值治疗后升高,并高于对照组。结论:参麦注射液联合化疗NSCLC可提高疗效,减轻毒副作用,改善生存质量,提高机体的细胞免疫功能。Objective:To evaluate the efficacy of Shenmei injection and GP chemotherapy for treatmen of inoperable nonsmall cell lung cancer.Methods:All of 61 patients with NSCLC were divided into two groups:the experiment group(n=31)and the control group(n=30).Control group received GP chemotherapy only,and the experiment group was given Shenmei injection combined with GP chemotherapy.The date were recorded and analyzed for all cases.Results Compared with control patients (which was40%),the experiment group was 45.2%. PR+CR+MDreach74.2%.That resuls show that KPS for the experiment group is supurior to control group.The patients CD4/ CD8 was enhanced.Conclusion The regimen of Shenmei injection in combination with GP is effective ,safe and well-tolerance in the treatment of NSCLC. At the same time It improve the body’scellular immune function.

关 键 词：参麦注射液 非小细胞肺癌 GP方案化疗 

分 类 号：R734.2[医药卫生—肿瘤]